Pertussis vaccines and methods of making and using
Bordetella pertussis iron receptor proteins or portions thereof (e.g., one or more extracellular domains), alone or spliced into B. pertussis scaffold proteins (e.g., fimbrial or flagellin), are provided and can be used in acellular vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals. In addition, Bordetella species grown under iron-starved conditions are provided and can be used in whole cell vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals.
1. A chimeric polypeptide comprising at least one Bordetella antigenic polypeptide comprising an iron receptor protein or an antigenic portion thereof spliced into a Bordetella scaffold protein selected from a fimbrial protein, a flagellin protein, and combinations thereof.
2. The chimeric polypeptide of claim 1 , wherein the antigenic portion of an iron receptor protein comprises at least one extracellular domain.
3. The chimeric polypeptide of claim 1 , wherein the iron receptor protein is a TonB-dependent receptor protein or an antigenic portion thereof.
4. The chimeric polypeptide of claim 3 , wherein the TonB-dependent receptor protein is a ferric enterobactin siderophore (BfeA) receptor protein.
5. The chimeric polypeptide of claim 1 , wherein the iron receptor protein is a hemin or hemoprotein receptor or an antigenic portion thereof.
6. The chimeric polypeptide of claim 5 , wherein the hemin or hemoprotein receptor is a BhuR protein.
7. The chimeric polypeptide of claim 1 , wherein the iron receptor protein is a siderophore receptor or an antigenic portion thereof.
8. The chimeric polypeptide of claim 7 , wherein the siderophore receptor is an alcaligin siderophore receptor (FauA).
9. The chimeric polypeptide of claim 1 , wherein the fimbrial protein is a fimbrial 2 protein or fimbrial 3 protein.
10. The chimeric polypeptide of claim 1 , wherein the flagellin protein is a flagellin subunit protein.
11. An acellular immunogenic composition, comprising the chimeric polypeptide of claim 1 and a pharmaceutically acceptable carrier.
12. The acellular vaccine of claim 11 , further comprising an adjuvant.